-+ 0.00%
-+ 0.00%
-+ 0.00%

Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium

Benzinga·08/25/2026 11:33:04
Listen to the news

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium.